Alpha Tau Medical Ltd (DRTS) has released an update.
Alpha Tau Medical Ltd. has reported promising results from a pooled analysis of clinical trials published in the Cancers journal, showing nearly 100% initial response rates and 89% complete response rates for various hard-to-treat cancers with its Alpha DaRT™ therapy. The long-term data, with up to 51 months of follow-up, indicates no significant toxicities and a two-year local recurrence-free survival rate of 77%, suggesting a potential new pathway for treating these challenging conditions. The company’s ongoing research aims to further evaluate the safety and efficacy of this innovative treatment.
For further insights into DRTS stock, check out TipRanks’ Stock Analysis page.
